Nuvalent
Michael Walsh is a Senior Scientist at Nuvalent, Inc. since February 2024, previously serving as a Scientist in Translational Medicine at Massachusetts General Hospital from November 2022 to February 2024. At Massachusetts General Hospital, Michael coordinated the tissue processing for clinical trials and performed advanced sequencing analysis. Prior to that, Michael completed a postdoctoral fellowship at Harvard University, where significant research was conducted under prominent professors. Experience also includes a Technical Research Assistant position at Brigham and Women's Hospital, focusing on the Epstein-Barr virus, and honors research at Bowdoin College. Michael holds a Ph.D. in Virology from Harvard University and a B.A. in Biology from Bowdoin College.
This person is not in any teams
This person is not in any offices
Nuvalent
1 followers
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.